These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12505230)

  • 1. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
    Bradham WS; Gunasinghe H; Holder JR; Multani M; Killip D; Anderson M; Meyer D; Spencer WH; Torre-Amione G; Spinale FG
    J Am Coll Cardiol; 2002 Dec; 40(12):2165-73. PubMed ID: 12505230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
    Stroud RE; Deschamps AM; Lowry AS; Hardin AE; Mukherjee R; Lindsey ML; Ramamoorthy S; Zile MR; Spencer WH; Spinale FG
    J Card Fail; 2005 Mar; 11(2):124-30. PubMed ID: 15732032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
    Peterson JT; Li H; Dillon L; Bryant JW
    Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.
    Purcell BP; Barlow SC; Perreault PE; Freeburg L; Doviak H; Jacobs J; Hoenes A; Zellars KN; Khakoo AY; Lee T; Burdick JA; Spinale FG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H814-H825. PubMed ID: 29979624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
    Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix Metalloproteinases Increase Because of Hypoperfusion in Obstructive Hypertrophic Cardiomyopathy.
    Bi X; Yang C; Song Y; Yuan J; Cui J; Hu F; Qiao S
    Ann Thorac Surg; 2021 Mar; 111(3):915-922. PubMed ID: 32738221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction.
    Mukherjee R; Snipes JM; Saunders SM; Zavadzkas JA; Spinale FG
    J Surg Res; 2012 Jan; 172(1):59-67. PubMed ID: 20863528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).
    Bonnema DD; Webb CS; Pennington WR; Stroud RE; Leonardi AE; Clark LL; McClure CD; Finklea L; Spinale FG; Zile MR
    J Card Fail; 2007 Sep; 13(7):530-40. PubMed ID: 17826643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury.
    Zheng K; Li C; Shan X; Liu H; Fan W; Wang Z; Zheng P
    Neurol India; 2013; 61(6):606-9. PubMed ID: 24441327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice.
    Zavadzkas JA; Stroud RE; Bouges S; Mukherjee R; Jones JR; Patel RK; McDermott PJ; Spinale FG
    Circ Res; 2014 Apr; 114(9):1435-45. PubMed ID: 24637197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W; Zhang HT; Yang XL
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction.
    Fertin M; Lemesle G; Turkieh A; Beseme O; Chwastyniak M; Amouyel P; Bauters C; Pinet F
    PLoS One; 2013; 8(8):e71280. PubMed ID: 23967183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.